Cargando…

Efficacy and Safety of TurmXTRA® 60N in Delayed Onset Muscle Soreness in Healthy, Recreationally Active Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial

BACKGROUND: Delayed onset of muscle soreness (DOMS) and its physiological consequences influenced an individual's adherence to an exercise routine. OBJECTIVE: This study aimed to evaluate the efficacy, safety, and tolerability of TurmXTRA® 60N (WDTE60N) on DOMS compared to placebo in recreation...

Descripción completa

Detalles Bibliográficos
Autores principales: Thanawala, Shefali, Shah, Rajat, Karlapudi, Vasu, Desomayanandam, Prabakaran, Bhuvanendran, Arun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374544/
https://www.ncbi.nlm.nih.gov/pubmed/35966736
http://dx.doi.org/10.1155/2022/9110414
_version_ 1784767804678864896
author Thanawala, Shefali
Shah, Rajat
Karlapudi, Vasu
Desomayanandam, Prabakaran
Bhuvanendran, Arun
author_facet Thanawala, Shefali
Shah, Rajat
Karlapudi, Vasu
Desomayanandam, Prabakaran
Bhuvanendran, Arun
author_sort Thanawala, Shefali
collection PubMed
description BACKGROUND: Delayed onset of muscle soreness (DOMS) and its physiological consequences influenced an individual's adherence to an exercise routine. OBJECTIVE: This study aimed to evaluate the efficacy, safety, and tolerability of TurmXTRA® 60N (WDTE60N) on DOMS compared to placebo in recreationally active healthy subjects. METHODS: This randomized, double-blind, placebo-controlled parallel-group study enrolled 30 healthy and recreationally active subjects (average age: 28.23 ± 4.20 years) and randomized them to receive WDTE60N (WDTE60N group; n = 15) or placebo (placebo group; n = 15). Study treatments were initiated 29 days before the eccentric exercise and were continued for 4 days after the exercise. The primary endpoint was the change in pain intensity measured by the visual analog scale (VAS) at the end of study treatment (at 96 hours after eccentric exercise) from baseline (measured immediately after exercise). RESULTS: The VAS score indicated that subjects from the WDTE60N group reported significantly less pain after eccentric exercise compared to the placebo group (AUC(0–96h): 286.8 ± 46.7 vs. 460 ± 40.5, respectively; p < 0.0001). Well-being status was assessed using the adapted version of the Hooper and MacKinnon questionnaire and was calculated as individual and cumulative scores of the domains (fatigue, mood, general muscle soreness, sleep quality, and stress) that demonstrated improvement in all domains and in overall well-being in the WDTE60N group compared to the placebo group (p < 0.0001). Serum lactate dehydrogenase (LDH) was significantly lower in the WDTE60N group compared to the placebo group (AUC(0–96h): 23623.7 ± 2532.0 vs. 26138.6 ± 3669.5, respectively; p=0.0446). CONCLUSION: Intake of WDTE60N before and after eccentric exercise significantly reduced subjective perception of muscle soreness and serum LDH activity and increased the psychological well-being in recreationally active subjects.
format Online
Article
Text
id pubmed-9374544
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-93745442022-08-13 Efficacy and Safety of TurmXTRA® 60N in Delayed Onset Muscle Soreness in Healthy, Recreationally Active Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial Thanawala, Shefali Shah, Rajat Karlapudi, Vasu Desomayanandam, Prabakaran Bhuvanendran, Arun Evid Based Complement Alternat Med Research Article BACKGROUND: Delayed onset of muscle soreness (DOMS) and its physiological consequences influenced an individual's adherence to an exercise routine. OBJECTIVE: This study aimed to evaluate the efficacy, safety, and tolerability of TurmXTRA® 60N (WDTE60N) on DOMS compared to placebo in recreationally active healthy subjects. METHODS: This randomized, double-blind, placebo-controlled parallel-group study enrolled 30 healthy and recreationally active subjects (average age: 28.23 ± 4.20 years) and randomized them to receive WDTE60N (WDTE60N group; n = 15) or placebo (placebo group; n = 15). Study treatments were initiated 29 days before the eccentric exercise and were continued for 4 days after the exercise. The primary endpoint was the change in pain intensity measured by the visual analog scale (VAS) at the end of study treatment (at 96 hours after eccentric exercise) from baseline (measured immediately after exercise). RESULTS: The VAS score indicated that subjects from the WDTE60N group reported significantly less pain after eccentric exercise compared to the placebo group (AUC(0–96h): 286.8 ± 46.7 vs. 460 ± 40.5, respectively; p < 0.0001). Well-being status was assessed using the adapted version of the Hooper and MacKinnon questionnaire and was calculated as individual and cumulative scores of the domains (fatigue, mood, general muscle soreness, sleep quality, and stress) that demonstrated improvement in all domains and in overall well-being in the WDTE60N group compared to the placebo group (p < 0.0001). Serum lactate dehydrogenase (LDH) was significantly lower in the WDTE60N group compared to the placebo group (AUC(0–96h): 23623.7 ± 2532.0 vs. 26138.6 ± 3669.5, respectively; p=0.0446). CONCLUSION: Intake of WDTE60N before and after eccentric exercise significantly reduced subjective perception of muscle soreness and serum LDH activity and increased the psychological well-being in recreationally active subjects. Hindawi 2022-08-05 /pmc/articles/PMC9374544/ /pubmed/35966736 http://dx.doi.org/10.1155/2022/9110414 Text en Copyright © 2022 Shefali Thanawala et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Thanawala, Shefali
Shah, Rajat
Karlapudi, Vasu
Desomayanandam, Prabakaran
Bhuvanendran, Arun
Efficacy and Safety of TurmXTRA® 60N in Delayed Onset Muscle Soreness in Healthy, Recreationally Active Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial
title Efficacy and Safety of TurmXTRA® 60N in Delayed Onset Muscle Soreness in Healthy, Recreationally Active Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial
title_full Efficacy and Safety of TurmXTRA® 60N in Delayed Onset Muscle Soreness in Healthy, Recreationally Active Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial
title_fullStr Efficacy and Safety of TurmXTRA® 60N in Delayed Onset Muscle Soreness in Healthy, Recreationally Active Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial
title_full_unstemmed Efficacy and Safety of TurmXTRA® 60N in Delayed Onset Muscle Soreness in Healthy, Recreationally Active Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial
title_short Efficacy and Safety of TurmXTRA® 60N in Delayed Onset Muscle Soreness in Healthy, Recreationally Active Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial
title_sort efficacy and safety of turmxtra® 60n in delayed onset muscle soreness in healthy, recreationally active subjects: a randomized, double-blind, placebo-controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374544/
https://www.ncbi.nlm.nih.gov/pubmed/35966736
http://dx.doi.org/10.1155/2022/9110414
work_keys_str_mv AT thanawalashefali efficacyandsafetyofturmxtra60nindelayedonsetmusclesorenessinhealthyrecreationallyactivesubjectsarandomizeddoubleblindplacebocontrolledtrial
AT shahrajat efficacyandsafetyofturmxtra60nindelayedonsetmusclesorenessinhealthyrecreationallyactivesubjectsarandomizeddoubleblindplacebocontrolledtrial
AT karlapudivasu efficacyandsafetyofturmxtra60nindelayedonsetmusclesorenessinhealthyrecreationallyactivesubjectsarandomizeddoubleblindplacebocontrolledtrial
AT desomayanandamprabakaran efficacyandsafetyofturmxtra60nindelayedonsetmusclesorenessinhealthyrecreationallyactivesubjectsarandomizeddoubleblindplacebocontrolledtrial
AT bhuvanendranarun efficacyandsafetyofturmxtra60nindelayedonsetmusclesorenessinhealthyrecreationallyactivesubjectsarandomizeddoubleblindplacebocontrolledtrial